- Trial phase
- Phase 2 (failed)
- Time to market
- Uncertain. J&J is evaluating exploratory data to decide whether to continue development. With two Phase 2 failures in different indications, the program's path to approval is highly uncertain and likely several years away if development continues at all.
- Why 3/10
- No hard dated binary catalyst is scheduled for PIPE-307 in the next ~12 months. J&J is evaluating exploratory data from the failed MOONLIGHT-1 trial but has not announced a decision date. The drug has already failed two Phase 2 trials, removing any near-term binary event. The company's focus has shifted to its wholly owned PIPE-791 program.
Watch for J&J's decision on PIPE-307's future, which could come at any time. A termination would remove any remaining upside from milestone payments and royalties, while a decision to continue into another trial would be a modest positive surprise. The more consequential catalyst for CTNM as a whole is the ongoing Phase 2 PROPEL-IPF trial of PIPE-791 (completion expected June 2028), but that is years away.
Price Chart
Executive Summary
PIPE-307 is an oral M1 muscarinic receptor antagonist being developed by Contineum Therapeutics (Nasdaq: CTNM) in partnership with Johnson & Johnson. The drug has failed two Phase 2 clinical trials: the VISTA trial in relapsing-remitting multiple sclerosis (November 2025) and the MOONLIGHT-1 trial in major depressive disorder (September 2026). Both missed their primary efficacy endpoints, though safety was acceptable. J&J is now evaluating exploratory data to determine the program's future, with no announced decision date. Contineum holds $244.5M in cash (runway through mid-2029) and has shifted strategic focus to its wholly owned PIPE-791 program for idiopathic pulmonary fibrosis.
How It Works
PIPE-307 is an oral small molecule that blocks the M1 muscarinic receptor (M1R) in the brain. By blocking this receptor, the drug aims to promote the repair of myelin (the protective coating around nerve fibers) in multiple sclerosis, and was also tested for its potential antidepressant effects in major depressive disorder.
Trial Status
PIPE-307 has completed two Phase 2 trials, both of which failed to meet their primary efficacy endpoints. The Phase 2 VISTA trial (NCT06083753) in relapsing-remitting multiple sclerosis (RRMS) enrolled 168 patients and missed its primary endpoint of change in binocular low contrast letter acuity, as well as all secondary efficacy endpoints (topline reported November 20, 2025). The Phase 2 MOONLIGHT-1 trial (NCT06785012) in major depressive disorder (MDD) also failed to meet its primary endpoint of improvement in MADRS total score at Day 5 versus placebo (topline reported September 14, 2026). Both trials showed acceptable safety and tolerability.
The Two-Sided Case
Upcoming Catalysts
- J&J decision on whether to continue PIPE-307 development (no date announced)
- Q3 2026 earnings call on November 11, 2026 (company-level catalyst, not drug-specific)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Contineum Therapeutics, Inc. 8-K CTNM ·Originating report